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Abstract
The molecular defect in the abnormal fibrinogen Dusart (Paris
V) that is associated with thrombophilia was determined by
sequence analysis of genomic DNA that had been amplified
using the polymerase chain reaction. The propositus was hetero-
zygous for a single base change (C -> T) in the Aa-chain gene,
resulting in the amino acid substitution Aa 554 Arg Cys.
Restriction analysis of the amplified DNA derived from the
family members showed that his father and his two sons were
also heterozygous. Electron microscopic studies on fibrin
formed from purified fibrinogen Dusart demonstrated fibers
that were much thinner than in normal fibrin. In contrast to the
previously observed defective binding of plasminogen, the bind-
ing of thrombospondin to immobilized fibrinogen Dusart was
similar to that of normal fibrinogen. Immunoblot analysis of
plasma fibrinogen demonstrated that a substantial part of the
fibrinogen Dusart molecules were disulfide-linked to albumin.
The plasma of the affected family members also contained fi-
brinogen-albumin complexes. Furthermore, small amounts of
high molecular weight complexes containing fibrinogen were
detected in all the heterozygous individuals. These data indi-
cate that the molecular abnormality in fibrinogen Dusart (Aa
554 Arg -n Cys) results in defective lateral association of the
fibrin fibers and disulfide-linked complex formation with albu-
min, and is associated with a family history of recurrent throm-
bosis in the affected individuals. (J. Clin. Invest. 1993.
91:1637-1643.) Key words: Aa chain * albumin, disulfide-
linked * dysfibrogenemia - gene analysis
Introduction
Release of the fibrinopeptides FpA and FpB from fibrinogen
exposes two types of polymerization sites, designated "A" and
"B," in the amino-terminal portion of the fibrin molecule (1)
that appear to function cooperatively in the fibrin self-assem-
bly process (2, 3). Complementary polymerization sites, desig-
nated "a" and "b," respectively, are located in the carboxyl-ter-
minal regions of the molecule (1). Fibrin assembly com-
mences with formation ofdouble-stranded fibrils (2-6), which
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then branch to form a three-dimensional matrix, concomitant
with lateral association of fibrils, that results in increased fiber
thickness (7-9). Fibril formation is predominantly due to in-
teraction between the A and a sites (4); interaction between B
and b sites contributes to lateral fibril association and augment
thick fiber formation (4, 9). It has recently been suggested that
the carboxyl-terminal region of the Aa chain constitutes an
important component of the b polymerization site in fibrino-
gen ( 10).
Congenital abnormal fibrinogens not only provide tools for
studying the structure-function relationship in fibrinogen, but
they also offer us an opportunity to determine the relationship
between the molecular defect and the clinical symptoms ofthe
affected individuals. More than 240 cases of inherited dysfi-
brinogenemia have been reported ( 1), of which 48 are asso-
ciated with clinically significant thromboembolic disease. In
one such case, fibrinogen Dusart, the functional defect is re-
lated to reduced plasminogen binding ( 12), impaired plasmin-
ogen activation by the tissue-type plasminogen activator (t-
PA' [ 13 ]), and abnormal fibrin polymerization ( 12).
In this paper we report the structural defect of fibrinogen
Dusart (Paris V), inferred from genetic analysis using PCR
( 14). The presence ofthe mutation in the family members and
the influence on fibrin polymerization was determined. The
additional cysteine created by the mutation was involved in the
formation of fibrinogen-albumin complexes in plasma. Fur-
thermore, the family history of recurrent thrombosis and the
analysis of the fibrinogen gene in the family members demon-
strate a convincing association between the molecular defect
and the thrombophilia.
Methods
Coagulation studies on plasma. Blood was collected by venepuncture
and anticoagulated with 0.1 vol of 0.13 M trisodium citrate. Platelet
poor plasma was prepared by centrifuging citrated blood at 2,000 g for
15 min at 150C. Thrombin and Reptilase clotting times were per-
formed as described before ( 15). Fibrinogen concentration was deter-
mined functionally according to Clauss ( 16) and immunologically ac-
cording to Mancini et al. ( 17 ). Antithrombin III activity was measured
by a chromogenic assay ( 18), protein C activity by using synthetic
substrate (Behringwerke, Marburg, FRG), and protein S by immunoas-
say (STAGO, Asnieres, France).
Protein purification. Fibrinogen was purified from plasma of the
propositus and a normal individual ( 19) and further analyzed as de-
scribed ( 12 ). Fibrinogen that lacked the carboxyl-terminal region was
prepared as described (20). Thrombospondin was purified from the
1. Abbreviations used in thispaper: HRP, horseradish peroxidase; t-PA,
tissue-type plasminogen activator.
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supernatant of thrombin-activated platelets by heparin-Sepharose af-
finity chromatography followed by Sepharose-4B gel filtration, essen-
tially as described by Margossian et al. (21 ) and modified as described
(22). The calcium concentration was maintained at 2 mM throughout
the purification procedure to avoid structural modification of the
thrombospondin molecule. Purified thrombospondin was radiolabeled
with carrier-free 1251I using the chloramine-T procedure to a specific
activity of - 0.2 MCi/Mg protein. The radiolabeled thrombospondin
had the same electrophoretic mobility as the unlabeled counterpart,
and exhibited specific and saturable binding to thrombin-activated
platelets (22). Protein concentrations were determined spectrophoto-
metrically at 280 nrfi, the A ' used for fibrinogen and thrombospon-
din were 15.0 and 10.4, respectively.
Electron microscopic studies onfibrin. Fibrin for critical-point dry-
ing was prepared by addition of human a-thrombin (0.1 U/ml final
concentration) to a solution of fibrinogen (50 ,g/ml in 50 mM Tris/
HCl, 100 mM NaCl, pH 7.4, buffer; ionic strength 0.14) followed by
incubation for 60 min at room temperature. A specimen of the fibrin
clot was picked up on a carbon-coated 200-mesh grid, fixed with glutar-
aldehyde/tannic acid, stained with uranyl acetate, dehydrated, and
then critical-point dried. Electron microscopy (EM) was carried out in
a model 400 electron microscope (Philips Electronic Instruments,
Mahwah, NJ) at 120 kV.
Binding of thrombospondin to fibrinogen. Microtiter wells were
coated in duplicate with 0.1 ml ofa 10 ,g/ml freshly prepared fibrino-
gen solution in 10 mM Tris/HCl, 150 mM NaCl, pH 7.4 (Tris buffer)
containing 2mM CaCl2, overnight at 22°C in a humid chamber. Wells
were rinsed twice with Tris buffer containing 2 mM CaCl2, 1 mM
MgCl2, and 0.05% (vol/vol) Tween 20 (Tris/Tween buffer), and sub-
sequently incubated for 1 h with Tris/Tween buffer containing 1.5%
(wt/vol) BSA. The wells were rinsed four times and incubated with
increasing concentrations of 1251-thrombospondin in Tris/Tween-
buffer for 3 h. The wells were washed four times with Tris/Tween
*buffer and cut out, and the radioactivity associated with each well was
counted. Nonspecific binding was determined by measuring the bind-
ing of '251-thrombospondin to wells coated only with BSA.
Immunoblot analysis ofplasma. SDS-PAGE was performed on
5-25% gradient gels according to Laemmli (23) or on 2-16% precast
gradient gels (Pharmacia, Uppsala, Sweden) using an electrophoresis
buffer containing 40 mM Tris, 20 mM sodium acetate, 2 mM diso-
dium EDTA, 0.2% (wt/ vol) SDS, pH 7.4, and a sample buffer contain-
ing 10 mM Tris/HCl, 1 mM disodium EDTA, 1% (wt/vol) SDS, pH
8.0. Molecular mass was estimated using a low M, calibration kit
(Pharmacia) containing proteins with an M, ranging from 14.4 to 94
kD or using a mixture of purified fibrinogen (340 kD), fibronectin
(450 kD) (purified from fibrinogen by affinity chromatography on
gelatin-Sepharose), and purified mouse monoclonal IgM (900 kD) (a
generous gift from Dr. R. Bos, Gaubius Laboratory).
Proteins from the SDS-PAGE gels were electroblotted onto nitro-
cellulose (24) for 16 h at 400 mA and 10°C. The nitrocellulose sheets
were blocked by incubating them in Tris/Tween buffer, pH 7.4, con-
taining 0.15 M NaCl, 0.5% (wt/vol) gelatin for 2 h. After blocking, the
blots were washed with Tris/Tween buffer and incubated for 2 h at
room temperature with mouse monoclonal antifibrinogen Y18 (25)
conjugated to horseradish peroxidase (HRP) diluted in Tris/Tween
buffer (kindly provided by Dr. W. Nieuwenhuizen, Gaubius Labora-
tory). Identical blots were incubated for 2 h at room temperature with
goat anti-human albumin conjugated to HRP (Nordic, Tilburg, The
Netherlands) diluted in Tris/Tween buffer. The protein bands reacting
with the different immunoconjugates were visualized by incubation
with a substrate solution containing 4-chloro- 1 -naphthol (26).
DNA amplification and sequencing. Genomic DNA was isolated
from blood cells as described (27). Oligonucleotides were synthesized
on a model 380A DNA synthesizer (Applied Biosystems, Inc., Foster
City, CA). Oligonucleotides 1i2a(5'GCCTCTAAGGTTGTAGGA-
ATTCTTCAG3') and #2b(5' ATCAGTGCACCCACCAAGTCT-
GGG3') were used to amplify the B# gene segment coding for amino
acids 9-72. Oligonucleotides a6a (5'GGCACGCTGGATGGG-
TTC3') and a6b (5'GGACTTACAGTCGACCACAAAAACAGA-
CC3') were used to amplify the part of the Aa-chain gene coding for
amino acids 492-625 anda 12 l-bp nontranslated 3'sequence. Oligonu-
cleotides ala (5TGTCTCCTCTTCTGGCTA3') and a2b (5'GTT-
ATTGGCTGAGGAAAAATCGCC3') were used to amplify the Aa
gene segment coding for amino acids 1-95. Oligonucleotides y4a
(5'GAAGCATCCTACGAAAGAGGG3') and y4b (5'AACTTG-
GAATCTAAGAAAGGAAAACTAACC3') and y5a (5'CTTCAT-
AGACTTGCAGAG3') and y5b (5'AAGCAAGTCGACTGTCCA-
ATAGGAAAAATA3') were used to amplify the y gene segment cod-
ing for amino acids 259-411. Amplification by PCR (14) was
performed in a 100-Ml reaction volume containing I Ag of genomic
DNA, 0.2 mM each of dATP, dCTP, dGTP, and dTTP (Pharmacia),
0.2MM each ofprimera and bin lx reaction buffer( 0mMTris/HCl,
pH 8.3, at 250C, 50 mM KCI, 3.0 mM MgCl2 and 0.001% [wt/vol]
gelatin). The DNA was denatured at 940C for 4 min and 2.0 U Taq
DNA polymerase (Perkin Elmer-Cetus, Norwalk, CT) was added. Cy-
cles consisted of a 1-min at 94°C, 0.5-min at 58°C, and 1.5-min at
72°C incubation. After 30 cycles, the amplified DNA was precipitated
with ethanol, dried, dissolved in 20 Ml of distilled water, and run on a
1.0% (wt/vol) ultra low gelling agarose gel (A-5030, Sigma Chemical
Co., St. Louis, MO). The bands with the appropriate size, as predicted
from the DNA sequence of the Aa ( I1), B# (28), and y (29) chain
genes were cut out ofthe gel in a volume of - 20 Al and heated to 55°C.
I Al of the melted agarose, containing - 10 ng of DNA, was mixed
with I Ml of the appropriate amplification primer (60 ng), and 2 Ml of
5X annealing buffer (T7 sequence kit, Pharmacia), the volume was
brought up to 14 Ml with distilled water. The mixture was heated to
95°C for 3 min and immediately after this was put on ice, and labeling
(5 min) and termination (10 min) reactions were performed using the
T7 DNA sequence kit according to the manufacturer's instructions.
Detection of mutation in family members by restriction analysis.
PCR samples containing the Aa fragment from the family members
were incubated with the restriction endonuclease BSAJ I (New En-
gland Biolabs, Beverly, MA) according to the manufacturer's instruc-
tions. After incubation the restriction digests were analyzed on a 2%
(wt/vol) agarose gel (A-6013, Sigma Chemical Co.) and stained with
ethidium bromide. DNA molecular size markers were prepared by Rsa
I (New England Biolabs) digestion ofM13mpl8 DNA.
Results
Case report and laboratory data. The propositus (11.2 in Fig. 1)
is a male Caucasian who developed spontaneous phlebitis at
the age of 37 yr, which was treated by heparin followed by oral
anticoagulant. At the age of41 yr, he suffered from pulmonary
embolism and deep vein thrombosis ofthe left leg. The throm-
I1 1.2
(.
'1.1 EII. 2 \j.3
1II.1 111.2 A11.3 111.4
Figure 1. Pedigree of the Dusart family. The arrow indicates the pro-
positus. Symbols used: (0) male, (o) female, (-) thrombotic disorder,
(m) fatal thrombotic disorder, (a) treated prophylactically with oral
anticoagulant.
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Table I. Summary ofLaboratory Data ofthe Propositus with Fibrinogen Dusart (HL2) and His Family Members
I. 1 1.2 II. 1 11.2 1I.3 111.1 111.2 III.3 I1.4
Heterozygous CGT
(Aa 554 Arg) -- TGT (Cys)
mutation in genomic DNA Yes ND ND Yes ND Yes Yes No No
Prolonged thrombin clotting
time in plasma Yes No ND Yes Yes Yes Yes No No
Disulfide-linked fibrinogen-
albumin complexes in plasma Yes ND ND Yes ND Yes Yes No No
ND, not determined.
bin clotting time ofthe propositus was prolonged (35 s, control
20 s) as well as the Reptilase clotting time (29.5 s, control 20 s).
His father (I.1 ) developed three episodes of spontaneous deep
vein thrombosis at the age of46 yr. At the age of52 yr he had an
episode of pulmonary embolism, and between the age of 54
and 70 yr he developed three episodes of thrombotic disorder
(deep vein thrombosis and superficial thrombosis). At the age
of76 yr he suffered a pulmonary embolus confirmed by angiog-
raphy without accompanying evidence of deep venous throm-
bosis. The thrombin and Reptilase clotting times of the father
were also prolonged. Two brothers (II. 1 and I1.3) ofthe propo-
situs died at the age of20 and 30 yr, respectively, from pulmo-
nary embolism after several episodes of thrombophlebitis.
Brother 11.3 showed a prolonged thrombin clotting time;
brother 11. 1 was not investigated. The two sons (Il. 1 and III.2)
of the propositus were born respectively in 1962 and 1964;
both had prolonged thrombin and Reptilase clotting times.
They were treated prophylactically with oral anticoagulants
from 1981 and no history of thrombosis was reported. Two
nieces (111.3 and III.4) had normal thrombin and Reptilase
clotting times and no history of thrombotic disorders (see also
Table I). Antithrombin III, protein C and protein S levels,
determined in the plasma ofthe propositus (11.2) and his father
(I. 1 ) during an interruption oforal anticoagulant therapy, were
all within the normal range.
Amplification and direct sequencing ofgenomic DNA frag-
ments. Based on the evidence suggesting that lateral association
of fibrin fibrils was impaired (see below), we amplified the
genomic DNA coding for the amino terminus of the Aa chain
(amino acids 1-95) and BB chain (amino acids 9-72), and the
G A T C
*w_
%W
_-0 Figure 2. Part of the DNA sequence of
the amplified Aa-chain gene fragment
coding for amino acids 492-61 1. Direct
sequence analysis of the amplified frag-
ment demonstrated a heterozygous mu-
tation at the position indicated by the
arrow.
carboxy terminus of the Aa chain (amino acids 492-625) and
'y chain (amino acids 259-411) of the fibrinogen molecule.
After amplification, fragments with the size predicted from the
genomic DNA sequence for the Aa, Bf3, and y chain genes were
sequenced. The fragments containing the DNA sequence cod-
ing for the amino-terminal segments of the Aa chain and B#
chain and the carboxyl-terminal segment of the -y chain were
completely normal. The fragment containing the DNA encod-
ing the carboxyl-terminal segment of the Aa chain of fibrino-
gen Dusart II.2 had a single base substitution (Fig. 2) in the
codon normally coding for arginine at position 554. This muta-
tion changed the codon CGT (arginine) to TGT which codes
for cysteine. The normal sequence was also present in Dusart
11.2, indicating that the propositus was heterozygous for this
mutation.
Fibrin structure determined by electron microscopy. The
fibrin fibers formed from fibrinogen Dusart at physiological
pH and ionic strength were much thinner than the fibers pres-
ent in normal fibrin (Fig. 3), indicating impaired lateral associ-
ation ofthe fibrin fibrils formed from fibrinogen Dusart. These
results are consistent with previous observations that showed
low turbidity ofpolymerized fibrin Dusart compared with nor-
mal fibrin ( 12).
Binding of thrombospondin to fibrinogen. Thrombospon-
din binds to the carboxyl-terminal part of the fibrinogen Aa-
and Bf3-chain (30, 31 ), and is thought to be an inhibitor of
complex formation among fibrin, plasminogen, and t-PA (32).
As the mutation in fibrinogen Dusart is located in the carboxyl
terminus of the Aa-chain, the binding of thrombospondin to
immobilized fibrinogen Dusart was compared with binding to
normal fibrinogen. 125I-thrombospondin bound to normal fi-
brinogen and fibrinogen Dusart in a concentration-dependent
manner (Fig. 4). Thrombospondin binding to fibrinogen lack-
ing the carboxyl-terminal segment containing amino acids
491-61 1 was reduced - 74% as compared to intact fibrinogen
(data not shown). The specificity of the binding to fibrinogen
was demonstrated by the fact that wells coated with only BSA
retained negligible amounts of 125I-thrombospondin. The bind-
ing of '25I-thrombospondin to fibrinogen Dusart was similar to
that of normal fibrinogen in terms of maximal amounts of
thrombospondin bound and apparent dissociation constants
(Kd = 1.3 X 1O-8 M, Fig. 3), indicating that the mutation in the
Aa-chain did not influence thrombospondin binding.
Detection of the mutation in family members. The muta-
tion found in the Aa gene fragment of fibrinogen Dusart abol-
ishes the recognition sequence (CCNNGG) for the restriction
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Figure 3. Electron microscopic images of fibrin formed by thrombin from (A) normal fibrinogen and (B) fibrinogen Dusart (bar, 500 nm; x27,
245).
endonuclease BSAJ I, which is found in the normal Aa gene
fragment. The loss of the restriction site at this position results
in the formation of a 275-bp band for the Aa fragment of
Dusart in place of the 25 l-bp band for normal Aa fragment.
Restriction analysis of the amplified Aa gene fragment from a
normal individual and the family members of the propositus
(Fig. 5) showed that the propositus (11.2), his father (I. 1), and
his two sons (III.1 and III.2) contained both the normal frag-
ment (251 bp) and the abnormal fragment (275 bp). These
results indicate that the father and the two sons of the proposi-
tus are also heterozygous for the mutation found in the propo-
situs. The normal individual and the two nieces (111.3 and















that they do not contain the mutation in the Aa gene fragment.
The DNA of the two brothers (II. 1 and 11.3 ) of the propositus
was not studied. However, one of them (II.3) showed a pro-
longed thrombin clotting time, indicating that he probably
contained the molecular defect (see also Table I).
Immunoblot analysis ofplasma. To determine whether the
additional cysteine created by the mutation in fibrinogen Du-
sart (Aa 554 Arg -- Cys) is involved in disulfide-linked com-
plex formation with other proteins (33-35), plasma ofthe pro-
positus, his siblings, and normal plasma was analyzed by immu-
noblotting after separation of plasma proteins on 2-16%
gradient SDS-PAGE gels. The blots were incubated with a
mouse monoclonal antifibrinogen antibody (Y18) and a goat
Figure 4. Binding of 1251-thrombospondin to immobi-
i lized normal fibrinogen (i), fibrinogen Dusart (A),
and BSA (-). The data are expressed as the total
2 amount of the relevant protein, and the total amount
bound to the well. Inset: Scatchard plot of binding
data.





Figure 5. EtBr stained gel of restriction digests by BSAJ I of amplified
Aa-chain gene fiagment from the propositus (II.2), his siblings (I.1,
111.1, III.2, III.3, and III.4) and a normal individual (N). DNA mo-
lecular size marker. M l 3mp18 Rsa I digest.
A
900-
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anti-human albumin antibody, both conjugated with HRP.
After reaction with Y18/HRP (Fig. 6 A), normal plasma and
the plasma of Dusart III.3 and 111.4 showed two intense bands
with Me's of - 340,000 and 300,000 D, corresponding to the
high- and low-Me form of fibrinogen (36, 37). Plasma of the
four other family members ofDusart (I. 1, 11.2, 111. 1, and 111.2)
contained the same two bands as normal plasma, and an addi-
tional intense band with a M, of 400,000 D. Several other
faint bands were also present in the plasma ofthese individuals
(1.2, II.2, 1. 1, and III.2). After reaction with goat anti-human
albumin/HRP (Fig. 6 B) normal plasma and plasma from
Dusart 111.3 and III.4 showed no bands which reacted with this
antibody. Plasma samples from Dusart 1. 1, 11.2, III. 1, and III.2
showed one intense band with an Mr of 400,000 D after reac-
tion with the goat anti-human albumin/HRP conjugate. As
indicated by the intense band with Mr 400,000 D, which
reacted with antifibrinogen and antialbumin antibodies, the
mutation in fibrinogen Dusart results in the formation ofcova-
lent complexes between the mutated fibrinogen and plasma
albumin. Immunoblot analysis of reduced plasma samples
with Y18/HRP (data not shown), did not show any high-Mr
complex, indicating that the complex formation involves disul-
fide bridges between the different proteins.
In summary, the presence ofthe mutation in the Aa-chain
of fibrinogen Dusart is accompanied by a prolonged thrombin
clotting time and the presence ofdisulfide-linked fibrinogen-al-
bumin complexes in plasma of the affected family members
(Table I).
Sulfhydryl content. To determine whether the cysteine resi-
due at position Aa 554 in fibrinogen Dusart had been oxidized
to disulfides, we evaluated the titratable sulfhydryl content us-
ing Ellman's reagent (38). The analysis was performed in the
presence of 8 M urea to denature the protein, because sulfhy-
dryl groups can be present in native proteins in a nontitratable
state (39). Calculation ofthe number of free sulfhydryl groups
showed that both normal fibrinogen and fibrinogen Dusart did
not contain any detectable free sulfhydryl groups (<0.05
mol/mol).
Discussion
Using the polymerase chain reaction, we identified a single-
base substitution in the gene coding for the Aa chain of the
abnormal fibrinogen Dusart. The mutation in fibrinogen Du-






Figure 6. Immunoblot of plasma of the propositus (11.2), his siblings
(I.1, III.1, 11I.2, 11I.3, and 111.4) and a normal individual (N) after
separation of the plasma proteins on a 2-16% gradient SDS-PAGE
gel, using (A) Y18/HRP, a monoclonal antibody specific for fibrino-
gen and (B) goat anti-human albumin/HRP.
sart is associated with abnormal fibrin polymerization ( 12),
reduced binding of Lys-plasminogen ( 12), and defective t-PA
induced plasminogen activation ( 13). Because the defect was
found to affect fibrin polymerization, genomic DNA segments
coding for the amino terminus of the Aa chain and the BB
chain, and the carboxy terminus of the Aa chain and y chain
were amplified. Sequence analysis of the amplified products,
demonstrated that the propositus (II.2) was heterozygous for a
single-base substitution in the codon for Aa Arg 554 (CGT)
resulting in a Cys (TGT) at this position. The absence oftitrat-
able sulfhydryl groups in fibrinogen Dusart indicated that the
additional cysteine residue at position Aa 554 had been oxi-
dized. Immunoblot analysis ofplasma from the propositus and
his family members demonstrated that, in all four heterozy-
gous family members, fibrinogen was linked to other proteins
by disulfide bonds. The predominant complex was identified
as a fibrinogen-albumin complex. The occurrence of a similar
complex was first described for the variant antithrombin III
molecule Northwick Park (33, 34) and recently for two abnor-
mal fibrinogens with an Arg -. Cys substitution in the amino
terminus of the fibrinogen BB-chain (35). The other faint
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bands present on the blot, could mean that a small amount of
fibrinogen Dusart is linked to other proteins as well. Intramo-
lecular disulfide bond formation between two abnormal Aa
chains in one fibrinogen molecule could also occur.
It has been known for many years (40) that fibrin polymers
formed from fibrinogen lacking carboxyl-terminal regions of
Aa chains develop less turbid clots, suggesting that fibers in the
clot matrix are reduced in thickness. Recent studies by Hase-
gawa and Sasaki ( 10) provided direct evidence that this region
ofthe Aa chain plays a critical role in the process oflateral fibril
association, and constitutes all or part of the so-called b poly-
merization site in the fibrin molecule. Electron-microscopic
images of the fibrin formed from fibrinogen Dusart showed a
marked reduction in the width of fibrin fibers in the clot ma-
trix. These observations support the conclusion that the car-
boxyl-terminal region of the Aa chain plays an important role
in lateral fibril association. Whether the substitution of cys-
teine at Aa 554, per se, or whether the albumin molecules
bound to the fibrinogen at this position cause the defective
function, cannot yet be deduced.
Removal of the carboxyl-terminus from fibrinogen Dusart
by limited plasmin digestion nearly normalized fibrin polymer-
ization (20), indicating that the remaining part of fibrinogen
Dusart contained no mutation which could explain the im-
paired fibrin polymerization. Moreover, sequence analysis of
amplified DNA coding for the terminal parts of fibrinogen,
which are involved in fibrin polymerization, did not reveal any
structural defect.
Previous reports on fibrinogen Dusart demonstrated that
fibrin formed from it had a reduced binding of Lys-plasmino-
gen ( 12) and a reduced accelerating effect on t-PA-induced
plasminogen activation ( 13). An explanation for these effects
could be that Aa Arg 554 is part of a plasminogen binding site
in normal fibrin, or that the presence of albumin, linked to Act
Cys 554, masks this binding site in fibrin Dusart. However,
thrombospondin, thought to bind to the carboxyl-terminal end
of the fibrinogen Act chain (31 ), bound normally to fibrinogen
Dusart. Another explanation is that the functional defects re-
lated to fibrinolysis are the result ofthe impaired lateral associa-
tion of fibrin fibrils in fibrin Dusart. The latter explanation is in
agreement with the observation that inhibition of fibrin poly-
merization reduces the acceleratory effect of fibrin on t-PA-in-
duced plasminogen activation (40-43). Further evidence for
this hypothesis is presented by Mirshahi et al. (44) who showed
that fibrin formed from low-Mr fibrinogen, which results in
reduced lateral association (10), is more resistant to fibrinoly-
sis induced by t-PA than fibrin prepared from high-Mr fi-
brinogen.
Restriction analysis of the Aa gene fragments demon-
strated that the three family members with a prolonged throm-
bin clotting time (. 1, III. 1, and 111.2) were also heterozygous
for the defect, whereas the two family members with a normal
thrombin clotting time (111.3 and 111.4) did not contain the
mutated DNA sequence. From the family history of recurrent
and massive thrombosis and the genetic analysis of the family
members, the association of the clinical symptoms with the
defect in fibrinogen Dusart is convincing. The mechanism re-
sponsible for the recurrent thrombosis in this family is most
likely related to the decreased plasminogen binding to fibrin
and the reduced acceleratory effect of fibrin on t-PA-induced
plasminogen activation. This would indicate that the cofactor
function of fibrin in regulating fibrinolysis is an important in
vivo mechanism for inducing efficient thrombolysis and for
preventing the occurrence of thrombosis.
Acknowledgments
We like to thank the patients, who gave their consent for frequent
blood examinations, and Dr. Dana Fowlkes for synthesizing the oligo-
nucleotides.
This work was supported by National Institutes of Health grants
HL-31048 (Dr. Lord), and HL-28444 (Dr. Mosesson), NATO grant
CR6 860110, and a grant of the Dutch Thrombosis Foundation.
References
1. Kudryk, B. J., D. Collen, K. R. Woods, and B. Blomback. 1974. Evidence
for localization of polymerization sites in fibrinogen. J. Biol. Chem. 249:3322-
3325.
2. Shainoff, J. R., and B. N. Dardik. 1979. Fibrinopeptide B and aggregation
of fibrinogen. Science (Wash. DC). 204:200-202.
3. Shainoff, J. R., and B. N. Dardik. 1983. Fibrinopeptide B in fibrin assembly
and metabolism: physiologic significance in delayed release of the peptide. Ann.
N.Y. Acad. Sci. 408:254-268.
4. Olexa, S. A., and A. Z. Budzynski. 1980. Evidence for four different poly-
merization sites involved in human fibrin formation. Proc. Natl. Acad. Sci. USA.
77:1374-1378.
5. Olexa, S. A., A. Z. Budzynski, R. F. Doolittle, B. A. Cottrell, and T. C.
Greene. 1981. Structure of fragment E species from human cross-linked fibrin.
Biochemistry. 21:6139-6145.
6. Budzynski, A. Z., S. A. Olexa, and B. V. Pandya. 1983. Fibrin polymeriza-
tion sites in fibrinogen and fibrin fragments. Ann. N.Y. Acad. Sci. 408:301-314.
7. Carr, M. E., Jr., L. L. Shen, and J. Hermans. 1977. Mass-length ratio of
fibrin fibers from gel permeation and light scattering. Biopolymers. 16:1-15.
8. Hantgan, R. R., andJ. Hermans. 1979. Assembly of fibrin: alight scattering
study. J. Biol. Chem. 254:11272-1 1281.
9. Mosesson, M. W. 1990. Fibrin polymerization and its regulatory role in
hemostasis. J. Lab. Clin. Med. 116:8-17.
10. Hasegawa, N., and S. Sasaki. 1990. Location of the binding site "b" for
lateral polymerization of fibrin. Thromb. Res. 57:183-195.
1 1. Ebert, R. F., editor. 1991. Index of Variant Human Fibrinogens, 1991
Edition. CRC Press, Boca Raton, FL.
12. Soria, J., C. Soria, and J. P. Caen. 1983. A new type of congenital dysfi-
brinogenaemia with defective fibrin lysis-Dusard syndrome: possible relation to
thrombosis. Br. J. Haematol. 53:575-586.
13. Lijnen, H. R., J. Soria, C. Soria, D. Collen, and J. P. Caen. 1984. Dysfi-
brinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced
plasminogen activation. Thromb. Haemostasis. 51:108-109.
14. Saiki, R. K., D. H. Gelfand, S. Stoffel, S. J. Scharf, R. Higuchi, G. T. Horn,
K. B. Mullis, and H. A. Erlich. 1988. Primer directed enzymatic amplification of
DNA with a thermostable DNA polymerase. Science (Wash. DC). 39:487-491 .
15. Caen, J., M. J. Larrieu, and M. Samama. 1975. L'H6mostase, Methode
d'Exploration et de Diagnostic Pratique. L'Expansion Scientifique Francaise,
Paris.
16. Clauss, A. 1957. Gerinnungsphysiologische Schnellmethode zur Bestim-
mung des Fibrinogens. Acta. Haematol. 17:237-246.
17. Mancini, G., A. 0. Carbonara, and J. Heremans. 1965. Immunochemical
quantitation of antigens by single radial immunodiffusion. Immunochemistry.
2:235-254.
18. Abilgaard, U., 0. R. Odengard, and M. Lie. 1975. Heparin cofactor activ-
ity measured with an amidolytic method. Thromb. Diath. Haemorrh. 6:287-297.
19. Blomback, B., and M. Blomback. 1956. Purification ofhuman and bovine
fibrinogen. Ark. Kem. 10:415-443.
20. Siebenlist, K. R., M. W. Mosesson, J. P. DiOrio, J. Soria, C. Soria, and
J. P. Caen. 1991. The polymerization of fibrinogen Dusart (Aa 554 Arg - Cys)
after removal of carboxyl terminal regions of the Aa chains. Blood Coagulation
and Fibrinolysis. In press.
21. Margossian, S. S., J. W. Lawler, and H. S. Slayter. 1981. Physical character-
ization of platelet thrombospondin. J. Biol. Chem. 256:7495-7500.
22. Dubernard, V., and C. Legrand. 1991. Characterization of the binding of
thrombospondin to human platelets and its association with the platelet cytoskele-
ton. J. Lab. Clin. Med. 118:446-457.
23. Laemmli, U. K. 1970. Cleavage ofstructural proteins during the assembly
of the head of bacteriophage T4. Nature (Lond.). 227:680-685.
1642 Koopman et al.
24. Towbin, H., T. Staehelin, and J. Gordon. 1979. Electrophoretic transfer of
proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some
applications. Proc. Natl. Acad. Sci. USA. 76:4350-4354.
25. Koppert, P. W., C. M. G. Huijsmans, and W. Nieuwenhuizen. 1985. A
monoclonal antibody, specific for human fibrinogen, fibrinopeptide A-contain-
ing fragments and not reacting with free fibrinopeptide A. Blood. 66:503-507.
26. Hong, C. S., B. M. Stadler, M. Wdlti, and A. L. De Weck. 1986. Dot-im-
munobinding assay with monoclonal anti-IgE antibodies for the detection and
quantitation of human IgE. J. Immunol. Methods. 95:195-202.
27. Gustafson, S., J. A. Proper, E. J. W. Bowie, and S. S. Sommer. 1987.
Parameters affecting the yield of DNA from human blood. Anal. Biochem.
165:294-299.
28. Chung, D. W., B. G. Que, M. W. Rixon, M. Mace, Jr., and E. W. Davie.
1983. Characterization of complementary deoxyribonucleic acid and genomic
deoxyribonucleic acid for the # chain of human fibrinogen. Biochemistry.
22:3244-3250.
29. Rixon, M. W., B. W. Chung, and E. W. Davie. 1985. Nucleotide sequence
of the gene for the -y-chain of human fibrinogen. Biochemistry. 24:2077-2086.
30. Bacon-Baguley, T., B. J., Kudryk, and D. A. Walz. 1987. Thrombospon-
din interaction with fibrinogen: evidence for binding to the Aa and BB chains of
fibrinogen. J. Biol. Chem. 262:1927-1930.
31. Tuszynski, G. R., S. Srivastava, H. I. Switalska, J. C. Holt, C. S. Cier-
niewski, and S. Niewiarowski. 1985. The interaction ofhuman platelet thrombo-
spondin with fibrinogen: thrombospondin purification and specificity of interac-
tion. J Biol. Chem. 260:12240-12245.
32. Silverstein, R. L., L. L. K. Leung, P. C. Harpel, and R. L. Nachman. 1984.
Complex formation of platelet thrombospondin with plasminogen: modulation
of activation by tissue activator. J. Clin. Invest. 74:1625-1633.
33. Erdjument, H., D. A. Lane, H. Ireland, M. Panico, V. Di Marzo, 1. Blench,
and H. R. Morris. 1987. Formation of a covalent disulfide-linked antithrombin-
albumin complex by an antithrombin variant, antithrombin "Northwick Park."
J. Biol. Chem. 262:13381-13384.
34. Erdjument, H., D. A. Lane, M. Panico, V. Di Marzo, and H. R. Morris.
1988. Single amino acid substitution in the reactive site of antithrombin leading
to thrombosis. J. Biol. Chem. 263:5589-5593.
35. Koopman, J., F. Haverkate, J. Grimbergen, L. Engesser, I. Novakova, A.
Kerst, and S. T. Lord. 1992. Abnormal fibrinogens Ijmuiden (B/3 Arg 14 -- Cys)
and Nijmegen (BB Arg 44 - Cys) form disulfide-linked fibrinogen-albumin
complexes. Proc. Nail. Acad. Sci. USA. 89:3478-3482.
36. Mosesson, M. W., D. K. Galanakis, and J. S. Finlayson. 1974. Compari-
son ofhuman plasma fibrinogen subfractions and early plasmic fibrinogen deriva-
tives. J. Biol. Chem. 249:4656-4664.
37. Lipinska, I., B. Lipinski, and V. Gurewich. 1974. Fibrinogen hetrogeneity
in human plasma: electrophoretic demonstration and characterization of two
major fibrinogen components. J. Lab. Clin. Med. 84:509-516.
38. Ellman, G. L. 1959. Tissue sulfhydryl groups. Arch. Biochem. Biophys.
82:70-77.
39. Takahashi, N., and M. Hirose. 1990. Determination ofsulfhydryl groups
and disulfide bonds in a protein by polyacrylamide gel electrophoresis. Anal.
Biochem. 188:359-365.
40. Mosesson, M. W., N. Alkjaersig, B. Sweet, and S. Sherry. 1967. Human
fibrinogen of relatively high solubility: comparative biophysical, biochemical,
and biological studies with fibrinogen of lower solubility. Biochemistry. 6:3279-
3287.
41. Suenson, E., and L. C. Petersen. 1986. Fibrin and plasminogen structures
essential to stimulation of plasmin formation by tissue-type plasminogen activa-
tor. Biochim. Biophys. Acta. 870:510-519.
42. Koopman, J., L. Engesser, M. Nieveen, F. Haverkate, and E. J. P. Brom-
mer. 1986. Fibrin polymerization associated with tissue-type plasminogen activa-
tor (t-PA) induced Glu-plasminogen activation. In Fibrinogen and Its Deriva-
tives: Biochemistry, Physiology and Pathophysiology. G. Muller-Berghaus, U.
Scheefers-Borchel, E. Selmayr, and A. Henschen, editors. Elsevier, Amsterdam.
315-318.
43. Soria, J., C. Soria, 0. Bertrand, M. Mirshahi, F. W. Dunn, E. Svenson, P.
Desvignes, P. Bonnet, M. Samama, and J. P. Caen. 1986. Role of fibrin polymer-
ization in fibrinolysis: comparison between polymerisable and unpolymerisable
fibrins in the potentiating effect of plasminogen activation by tissue-type plas-
minogen activator. In Fibrinogen-Fibrin Formation and Fibrinolysis, Volume
4. D. Lane, A. Henschen, and M. K. Jasani, editors. Walter de Gruyter & Co.,
Berlin. 153-158.
44. Mirshahi, M., J. Soria, and C. Soria. 1990. Fibrinogen populations in
plasma: differences in their degradability. In Fibrinogen 4: Current Basic and
Clinical Aspects. M. Matsuda, S. Iwanaga, A. Takada, and A. Henschen, editors.
Elsevier, Amsterdam. 123-130.
Molecular Defect in Fibrinogen Dusart Associated with Thrombophilia 1643
